Cel-Sci ($CVM), seeking $50 million from former partner inVentiv Health, will soon get its day in court against the CRO. The trial is set for May 4, the company said. In its arbitration claim, Cel-Sci alleges that inVentiv committed breach of contract and fraud in its handling of Phase III studies of Multikine, the biotech's immunotherapy for head and neck cancer. InVentiv, in a statement, has said that the suit is "nothing more than an attempt to avoid paying an outstanding debt. Cel-Sci's legal claims are meritless, and we will vigorously defend against the baseless allegations." More